Dexcom

DXCM · NASDAQ

$85.74−$0.24 (−0.28%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $85.98

DXCM analyst rating

BuyConsensus of 23 analysts over the last 12 months. 87% rate it a buy.

Strong buy0
Buy20
Hold2
Underperform1
Sell0

12-month price target · 29 analysts

Average $96.73 (+12.8% upside)

Low: $75.75
Now: $85.74
High: $120.75

Upgrades and downgrades

The latest rating actions, newest first

DXCM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 12, 2026	Maintains	Buy	$90.00 → $96.00	48%
Barclays	Oct 7, 2026	Initiates	Overweight	$115.00	68%
RBC Capital	Oct 1, 2026	Maintains	Outperform	$90.00 → $105.00	57%
Truist Securities	Sep 18, 2026	Maintains	Buy	$93.00 → $102.00	50%
TD Cowen	Sep 18, 2026	Maintains	Buy	$95.00	48%
Argus Research	Aug 4, 2026	Maintains	Buy	$86.00 → $96.00	67%
Canaccord Genuity	Aug 3, 2026	Maintains	Buy	$82.00 → $90.00	44%
Citigroup	Jul 31, 2026	Maintains	Buy	$84.00 → $88.00	60%
RBC Capital	Jul 31, 2026	Maintains	Outperform	$85.00 → $90.00	57%
Mizuho	Jul 31, 2026	Maintains	Outperform	$90.00 → $95.00	56%

The case for and against

Updated Oct 14, 2026

Bull case

DexCom is positioned for durable fundamental growth because its CGM platform is extending beyond intensive diabetes care into the large Type 2 non-insulin and broader consumer markets, where CONNECT showed a −1.6% A1c reduction versus −0.7% control, ~21% TIR improvement, and ~97% adherence. Its software-led Stelo experience, with frictionless meal logging, daily insights, and AI coaching, suggests retention and utilization can be driven by engagement rather than sensors alone, supporting a differentiated ecosystem and a scalable, profitable model. Financially, the company is already showing operating leverage, with adjusted gross margin of 63.5%, adjusted operating margin of 22.2%, adjusted EBITDA margin of 30.6%, and $2.42B of cash and marketable securities, while 2026 revenue guidance of $5.16B-$5.25B implies 11-13% organic growth.

Bear case

DexCom is facing a weakening fundamental case because sensor performance still has meaningful limitations, with compression lows during sleep or when lying on the sensor arm reducing overnight glucose-analysis reliability and creating a usability gap versus the company’s claims of convenience. Its outlook is also pressured by sector-level risks such as regulatory delays, pricing pressure from payors and CMS, and the high capital investment required to compete, all of which could make profitability difficult even if CGM adoption expands. In addition, the stock’s significant premium multiple leaves little room for disappointment if CGM penetration stalls, competitive products erode its moat, or new product launches are delayed.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.